+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients

Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients

Chinese Medical Journal 128(6): 727-732

We investigated whether and to what extent the ratio between circulating fibrinogen (Fg) and its degradation products (FDP) reflects the severity of coronary artery disease (CAD) in type 2 diabetic patients. Plasma levels of Fg and FDP were determined, and Fg/FDP ratio was calculated in 344 consecutive patients with type 2 diabetes and chest pain on exertion undergoing coronary angiography. The severity of CAD was evaluated by the number of significant CAD (>50% luminal diameter narrowing) and Gensini score. Plasma Fg was higher, but Fg/FDP ratio was lower in patients with significant CAD (n = 255) compared with those without (n = 89), due to a disproportionate increase in FDP. Fg and FDP correlated positively, while Fg/FDP ratio negatively, with the number of diseased coronary arteries and the tertile of Gensini score (all P values for trend < 0.01). After adjusting for age, sex, risk factors for CAD, lipid profiles, glycosylated hemoglobin A1c, creatinine, leukocyte count, and high-sensitivity C-reactive protein, Fg/FDP ratio remained an independent determinant for multivessel coronary disease (MVD) (odds ratio [OR], 0.869; 95% confidence interval [CI], 0.788-0.958, P = 0.005) and high tertile of Gensini score (OR, 0.797, 95% CI, 0.682-0.930, P = 0.004). The area under the curve of Fg/FDP ratio was larger than that of Fg for predicting the presence of MVD (0.647 vs. 0.563, P = 0.048) and Gensini score ≥ 30 (0.656 vs. 0.538, P = 0.026). Elevated plasma Fg and FDP level and reduced Fg/FDP ratio are associated with presence of CAD, and Fg/FDP ratio is superior to Fg in reflecting severe coronary atherosclerosis for patients with type 2 diabetes.

(PDF same-day service: $19.90)

Accession: 057427146

Download citation: RISBibTeXText

PMID: 25758263

DOI: 10.4103/0366-6999.152465

Related references

Measuring plasma fibrinogen levels in patients with liver cirrhosis: The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays. Thrombosis Research 78(4): 353-362, 1995

Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. Second report: Urinary fibrin/fibrinogen degradation products in nephrotic syndrome. (author' transl). Nihon Jinzo Gakkai Shi 20(4): 315-326, 1978

Use of monoclonal antibodies to fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. NATO ASI series Series A Life sciences19(219): 189-197, 1991

The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemporary Oncology 17(2): 113-119, 2013

Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 9(1): 109-121, 1989

Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy. Scandinavian Journal of Respiratory Diseases 59(4): 210-215, 1978

Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. First report: Urinary fibrin/fibrinogen degradation products in primary glomerulonephritis. Nihon Jinzo Gakkai Shi 20(1): 67-78, 1978

Ca binding of rat fibrinogen and fibrin(ogen) degradation products. Febs Letters 93(1): 177-180, 1978

Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC. Rinsho Byori. Japanese Journal of Clinical Pathology 41(12): 1349-1352, 1993

The effect of fibrinogen degradation products and some lysine analogues on the dissociation of plasmin(ogen)-fibrin complexes. Thrombosis Research 16(5-6): 705-713, 1979

Comparison of the potentiating effect of fibrinogen fibrinogen degradation products and fibrin degradation products on the amidolytic activity of the plasminogen strepto kinase complex improvement of plasminogen determination in biological samples by decreasing the influence of fibrin degradation products. Thrombosis & Haemostasis 50(1): 56, 1983

The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease. Diabetes Care 36(5): 1327-1334, 2013

Specific identification of fibrinogen polymers fibrinogen degradation products and crosslinked fibrin degradation products in defined clinical conditions application of a new sensitive assay. British Journal of Haematology 61(3): 564-565, 1985

Enhancement of amidolytic activity on chromogenic substrate of strepto kinase plasminogen complex induced by fibrin degradation products comparison of potentiator activity between fibrinogen fibrinogen degradation products d or e and fibrin split products early and late stages. Haemostasis 11(SUPPL 1): 98, 1982